Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method of identifying diagnostic reagents

a diagnostic reagent and reagent technology, applied in the field of diagnostic reagent identification, can solve the problems of inability to treat patients with beneficial therapy, heterogeneous tumors even from the same tissue or organ, and inability to identify tumors

Inactive Publication Date: 2010-11-18
VENTANA MEDICAL SYST INC
View PDF1 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

These diagnostic reagents specifically bind to RTKs in the absence of protein-protein interaction, providing accurate predictions of cancer aggressiveness and treatment responses, thereby optimizing therapy selection and patient outcomes.

Problems solved by technology

However, it is now apparent that tumors, even from the same tissue or organ, are heterogeneous on the cellular and / or molecular level.
This unpredictability confounds treatment selection and may expose patients to the risks and discomforts of unneeded therapies or may lead to failure to treat a patient with a beneficial therapy.
Now, a challenge is to use this information to identify useful diagnostic and therapeutic reagents to provide cancer patients with an accurate prediction of disease outcome and to administer “the appropriate drug, at the appropriate dose, at the appropriate time.”

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method of identifying diagnostic reagents
  • Method of identifying diagnostic reagents
  • Method of identifying diagnostic reagents

Examples

Experimental program
Comparison scheme
Effect test

example 1

An Exemplary Monoclonal Antibody Specific for EGFR Regulatory Domain

[0217]This Example describes an exemplary RD-binding molecule; more particularly a monoclonal antibody that binds an epitope in the EGFR inhibitory subdomain. This antibody has the added advantage that it will identify not only full-length EGFR, but also truncated mutant forms of EGFR, which have been shown to be constitutively activated (Pedersen et al., Ann. Oncol., 12(6):745-60, 2001). Similar methods can be used to identify antibodies for other RTK intracellular domains.

[0218]A computer program (DNASTAR™, Madison, Wis.) was used for the selection of immunogenic peptide sequences within the EGFR intracellular domain. The program examined the input protein sequence for short (e.g., less than 20 contiguous amino acids) sequences that likely had a high probability for producing an antibody response in animals immunized with immunogens including such short sequences.

[0219]One identified short sequence was LDNPDYQQDFF...

example 2

Exemplary Methods for Immunohistochemical Staining of Tissue with EGFR-Specific Antibodies

[0224]Immunohistochemistry is the well-known method and variations on such methods are readily determined with routine experimentation by those of ordinary skill in the art (see, e.g., Dabbs, Diagnostic Immunohistochemistry, Churchill Livingstone, 2002). Exemplary methods for detecting in FFPE tissue by manual IHC an EGFR RD-binding molecule (e.g., monoclonal antibody clone 5B7) or an antigen-binding molecule specific for the EGFR extracellular domain (e.g., monoclonal antibody clone 3C6) are provided in Table 10. One skilled in the art will recognize that similar methods provide in the Tables below can be used for diagnostic specific binding reagents for other RTKs.

TABLE 10Exemplary IHC MethodsStep #Manual IHC Assay0Fresh tissue is placed in a fixative (such as, 10% neutral buffered formalin) forapproximately 12-48 hours at room temperature. Then, the tissue is dehydratedthrough graded alcohol...

example 3

Antibody Specific for EGFR Regulatory Domain Epitope Unexpectedly does not Substantially Bind to Some EGFR-Positive Tissues

[0227]This Example demonstrates that RD-binding molecules, such as clone 5B7, exhibited differential binding to EGFR-positive tissues (as detected by an antibody specific for the EGFR external domain). As described in more detail below, but without being limited to a single theory, this differential binding is believed to be due to the differential expression of EGFR regulatory proteins (e.g., SOCS proteins like SOCS1 or SOCS3) in EGFR-positive tissues. Such regulatory proteins, when directly associated with the EGFR regulatory domain, mask the epitopes of RD-binding molecules.

[0228]A. Normal Human Tissues

[0229]The staining by IHC of antibodies specific for the EGFR regulatory domain (i.e., clone 5B7) and external domain (i.e., clone 3C6) in FFPE 30 normal human tissues were compared. Tissue arrays were obtained from USBiomax (Igamsville, Md.; Cat. No. FDA801). ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Disclosed herein are methods for identifying diagnostic reagents (e.g., antigen-binding molecules, such as antibodies) that are useful, for instance, as primary diagnostic, prognostic, and / or predictive (e.g., companion diagnostic) reagents in a disease state, such as cancer.

Description

CROSS REFERENCE TO RELATED APPLICATIONS[0001]This application claims priority to U.S. Provisional Application Nos. 60 / 949,792 filed Jul. 13, 2007 and 60 / 988,196 filed Nov. 15, 2007, herein incorporated by reference.FIELD OF THE DISCLOSURE[0002]This disclosure concerns a method for identifying diagnostic reagents (e.g., antigen-binding molecules, such as antibodies) that are useful, for instance, as primary diagnostic, prognostic, and / or predictive (e.g., companion diagnostic) reagents of a disease state, such as cancer.BACKGROUND[0003]Cancer is a generic name for a wide range of cellular malignancies characterized by unregulated growth, lack of differentiation, and the ability to invade local tissues and metastasize. These neoplastic malignancies affect, with various degrees of prevalence, every tissue and organ in the body. Historically, cancers have been diagnosed using conventional histological and clinical features of the affected tissue or organ. However, it is now apparent tha...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): G01N33/574G01N33/566C07K16/28
CPCC07K16/2863C07K2317/33C07K2317/34G01N2800/52G01N2333/71G01N2500/02G01N33/57484A61P35/00
Inventor POWELL, WILLIAM C.GORDON, DEBRA A.
Owner VENTANA MEDICAL SYST INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com